These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31277827)

  • 41. Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013.
    Pauwels K; Huys I; De Nys K; Casteels M; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):859-68. PubMed ID: 25978862
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Covering and Reimbursing Telehealth Services.
    Blackman K
    NCSL Legisbrief; 2016 Jan; 24(4):1-2. PubMed ID: 27032126
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bridging the NCAA's Accident Insurance Coverage Gaps? A Deep Dive into the Uncertainties of Injury Coverage in College Contact Sports, and the Impact that has on Athletes' Future Physical and Financial Comfort.
    Kline N
    J Law Health; 2018; 31(1):55-86. PubMed ID: 30889334
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
    Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
    Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reimbursement and value-based pricing: stratified cost-effectiveness analysis may not be the last word.
    Hawkins N; Scott DA
    Health Econ; 2011 Jun; 20(6):688-98. PubMed ID: 20568075
    [TBL] [Abstract][Full Text] [Related]  

  • 46. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
    Siebert U; Rochau U; Claxton K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Institute for Quality and Efficiency in Health Care: Germany.
    Nasser M; Sawicki P
    Issue Brief (Commonw Fund); 2009 Jul; 57():1-12. PubMed ID: 19639711
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Summarized Costs, Placement Of Quality Stars, And Other Online Displays Can Help Consumers Select High-Value Health Plans.
    Greene J; Hibbard JH; Sacks RM
    Health Aff (Millwood); 2016 Apr; 35(4):671-9. PubMed ID: 27044968
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions.
    Walker S; Sculpher M; Claxton K; Palmer S
    Value Health; 2012 May; 15(3):570-9. PubMed ID: 22583469
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Economic considerations for health insurance coverage of emerging genetic tests.
    Giacomini M; Miller F; O'Brien BJ
    Community Genet; 2003; 6(2):61-73. PubMed ID: 14560066
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Stakeholders' perceptions of ways to support decisions about health insurance marketplace enrollment: a qualitative study.
    Housten AJ; Furtado K; Kaphingst KA; Kebodeaux C; McBride T; Cusanno B; Politi MC
    BMC Health Serv Res; 2016 Nov; 16(1):634. PubMed ID: 27821121
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Key points of reform of the German health service 2003+. From the viewpoint of the Society of Private Practice Accounting Services].
    Urologe A; 2003 Jan; 42(1):136-8. PubMed ID: 14655650
    [No Abstract]   [Full Text] [Related]  

  • 53. Disparity in reimbursement for tuberculosis care among different health insurance schemes: evidence from three counties in central China.
    Pan Y; Chen S; Chen M; Zhang P; Long Q; Xiang L; Lucas H
    Infect Dis Poverty; 2016 Jan; 5():7. PubMed ID: 26812914
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Comparison of Coverage Restrictions for Biopharmaceuticals and Medical Procedures.
    Chambers J; Pope E; Bungay K; Cohen J; Ciarametaro M; Dubois R; Neumann PJ
    Value Health; 2018 Apr; 21(4):400-406. PubMed ID: 29680096
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Termination of Reimbursement of Arthroscopy in Osteoarthritis of the Knee: Is This Decision Based on Scientific Grounds?].
    Liebs TR; Berger S
    Z Orthop Unfall; 2017 Aug; 155(4):417-428. PubMed ID: 28675916
    [No Abstract]   [Full Text] [Related]  

  • 56. Pre-assessment to assess the match between cost-effectiveness results and decision makers' information needs: an illustration using two cases in rehabilitation medicine in The Netherlands.
    IJzerman MJ; Reuzel RP; Severens HL
    Int J Technol Assess Health Care; 2003; 19(1):17-27. PubMed ID: 12701936
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Guidelines and Value-Based Decision Making: An Evolving Role for Payers.
    McCauley JL
    N C Med J; 2015; 76(4):243-6. PubMed ID: 26509518
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation.
    Retèl VP; Steuten LMG; Geukes Foppen MH; Mewes JC; Lindenberg MA; Haanen JBAG; van Harten WH
    BMC Cancer; 2018 Sep; 18(1):895. PubMed ID: 30219040
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Uncertainties in real-world decisions on medical technologies.
    Lu CY
    Int J Clin Pract; 2014 Aug; 68(8):936-40. PubMed ID: 25074335
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.